Virtu Financial LLC Mirati Therapeutics, Inc. Transaction History

Virtu Financial LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 27, 2023	SELL	$36.13 - $49.49 $154,383 - $211,470	-4,273 Reduced 40.22%	6,350 $229,000
Q1 2023 May 01, 2023	BUY	$36.54 - $54.26 $388,164 - $576,403	10,623 New	10,623 $395,000
Q3 2022 Nov 07, 2022	SELL	$59.5 - $86.7 $38,496 - $56,094	-647 Reduced 6.43%	9,423 $658,000
Q2 2022 Aug 09, 2022	BUY	$39.16 - $88.71 $394,341 - $893,309	10,070 New	10,070 $676,000
Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $1.01 Million - $1.35 Million	-7,607 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$144.0 - $179.73 $1.1 Million - $1.37 Million	7,607 New	7,607 $1.23 Million
Q1 2021 May 19, 2021	SELL	$158.92 - $221.61 $299,723 - $417,956	-1,886 Closed	0 $0
Q4 2020 Feb 24, 2021	SELL	$162.05 - $240.27 $444,179 - $658,580	-2,741 Reduced 59.24%	1,886 $414,000
Q3 2020 Dec 11, 2020	BUY	$113.26 - $167.27 $524,054 - $773,958	4,627 New	4,627 $768,000
Q4 2019 Feb 04, 2020	SELL	$70.76 - $128.86 $267,189 - $486,575	-3,776 Closed	0 $0
Q3 2019 Nov 20, 2019	BUY	$77.91 - $109.6 $294,188 - $413,849	3,776 New	3,776 $294,000
Q2 2019 Aug 13, 2019	SELL	$59.49 - $104.71 $211,665 - $372,558	-3,558 Closed	0 $0
Q1 2019 Apr 12, 2019	BUY	$43.65 - $78.95 $155,306 - $280,904	3,558 New	3,558 $261,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.